ArticleBioinformation2026
Impact of comorbidities on D-dimer and CRP in covid-19 patients: A comparative retrospective analysis.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has posed significant challenges to healthcare systems, with inflammatory biomarkers emerging as important prognostic indicators. Therefore, it is of interest to evaluate the correlation between comorbidity burden and inflammatory markers-C-reactive protein (CRP) and D-dimer-in 100 hospitalized COVID-19 patients at a tertiary care center in Madhya Pradesh, India. Patients were categorized as non-comorbid (n=31), comorbid (n=30) and multimorbid (n=39), with a mean age of 53.18 ± 15.48 years and male predominance (63%). D-dimer and CRP levels were significantly higher in multimorbid patients compared to comorbid and non-comorbid groups (p<0.05). Thus, we show the importance of monitoring inflammatory biomarkers in COVID-19 patients with comorbidities for early identification of disease progression and targeted therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.